Evidence review · standard
ara 290 chemo neuropathy
Regeneration vs degeneration — where this fits
chemo neuropathy represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether ara-290 mechanisms address underlying repair deficits.
What is known
Studied for nerve repair and small-fiber regeneration in neuropathy models.
Target condition: chemo neuropathy. Body system: peripheral nerve.
Logic chain
- ara-290 studied for nerve repair and small-fiber regeneration in neuropathy models..
- chemo neuropathy involves peripheral nerve dysfunction.
- If ara-290 reaches the affected tissue, it may shift the repair/breakdown balance.
- This chain is tested in animal or lab models only.
Parent peptide claims relevant here
- ARA-290 is an 11-amino-acid peptide engineered from erythropoietin that selectively activates the innate repair receptor (IRR).
- In phase 2 trials, ARA-290 reduced neuropathic symptoms and improved quality of life in sarcoidosis small fiber neuropathy patients.
- ARA-290 treatment increased corneal nerve fiber density in sarcoidosis patients with initial reductions.
- In rodent sciatic and spared nerve injury models, ARA-290 reduced allodynia in a β-common receptor-dependent manner.
- Commercial vendors and clinics market this compound (17 commercial/clinic sources catalogued) — marketing material, not evidence.
Evidence tier
Preclinical — animal and in vitro studies only. No published human trials for this specific combination.
What we do not know
- Whether ara-290 reaches chemo neuropathy tissue at functional concentrations
- Optimal dosing, route, and duration for this target
- Interaction with standard-of-care treatments for chemo neuropathy
- Long-term safety profile in this population
Safety note
All peptide use for chemo neuropathy is research-context only. Not medical advice. Consult a physician before any experimental compound.
Key evidence
system
Combinatorial mapping (transparent): ara-290 vs chemo-neuropathy — regen=0.888, degen=0.88, Δ=0.007. Method: layer_relevance(0.95) × evidence_factor(0.85); catalog.degen_score for Chemotherapy-induced neuropathy (CIPN).
Model review1 contributions · 1 modelExpand the recursive review layer
1 / 1
Machine verification:
/api/articles/ara-290-chemo-neuropathy/contributionsAsk this article · 3 suggested prompts
Text the build (+14245134626) or WhatsApp — slug|question creates a question node. Paste evidence with ingest slug|q:NODE_ID|your paste.
What does the ledger say about this (system tier): "Combinatorial mapping (transparent): ara-290 vs chemo-neuropathy — regen=0.888, degen=0.88, Δ=0.007. Method: layer_relevance(0.95) × evidenc…"?
ask ara-290-chemo-neuropathy claim c_map_ara-290-chemo-neuropathy · paste includes §SELF
What can you answer from your catalogue about ara 290 chemo neuropathy — and what remains open or unverified?
ask ara-290-chemo-neuropathy gaps · paste includes §SELF
What are the strongest objections or counter-evidence on record against ara 290 chemo neuropathy?
ask ara-290-chemo-neuropathy objections · paste includes §SELF